Halozyme Therapeutics (HALO) Revenue (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Revenue of $376.7 million for Q1 2026, up 42.23% year-over-year from $264.9 million in Q1 2025, and down 16.61% quarter-over-quarter from $451.8 million in Q4 2025.
Halozyme Therapeutics (HALO) Revenue (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Revenue for 17 consecutive years, with $376.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 42.23% year-over-year to $376.7 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 39.12% YoY), while the FY2025 annual figure was $1.4 billion, up 37.55% from the prior year.
- Revenue slipped to $376.7 million in Q1 2026 per HALO's latest filing, from $451.8 million in the prior quarter.
- Across five years, Revenue topped out at $451.8 million in Q4 2025 and bottomed at $117.3 million in Q1 2022.
- Historically, Revenue has averaged $251.6 million across 5 years, with a median of $230.0 million in 2023.
- Annual changes were most pronounced in 2022 — Revenue surged 80.42% — and 2023, when it advanced 3.38%.
- Halozyme Therapeutics' Revenue stood at $181.5 million in 2022, then climbed by 26.75% to $230.0 million in 2023, then advanced by 29.55% to $298.0 million in 2024, then soared by 51.6% to $451.8 million in 2025, then dropped by 16.61% to $376.7 million in 2026.
- Business Quant data shows HALO's Revenue at $376.7 million in Q1 2026, $451.8 million in Q4 2025, and $354.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 481.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 481.00 Mn |
| Mar 31, 2026 | 376.71 Mn |
| Dec 31, 2025 | 451.77 Mn |
| Sep 30, 2025 | 354.26 Mn |
| Jun 30, 2025 | 325.72 Mn |
| Mar 31, 2025 | 264.86 Mn |
| Dec 31, 2024 | 298.01 Mn |
| Sep 30, 2024 | 290.08 Mn |
| Jun 30, 2024 | 231.35 Mn |
| Mar 31, 2024 | 195.88 Mn |
| Dec 31, 2023 | 230.04 Mn |
| Sep 30, 2023 | 216.03 Mn |
| Jun 30, 2023 | 221.04 Mn |
| Mar 31, 2023 | 162.14 Mn |
| Dec 31, 2022 | 181.50 Mn |
| Sep 30, 2022 | 208.98 Mn |
| Jun 30, 2022 | 152.37 Mn |
| Mar 31, 2022 | 117.28 Mn |
| Dec 31, 2021 | 102.00 Mn |
| Sep 30, 2021 | 115.83 Mn |